search
Back to results

Clinical vAliDation of ARTificial Intelligence in POlyp Detection (CAD-ARTIPOD)

Primary Purpose

Polyp of Colon

Status
Completed
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
artificial intelligence image processing
Sponsored by
Universitaire Ziekenhuizen KU Leuven
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Polyp of Colon focused on measuring colonic polyps, endoscopy, artificial intelligence

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age ≥40 years
  • Referral for screening, surveillance or diagnostic colonoscopy
  • Able to give informed consent by the patient or by a legal representative

Exclusion criteria for study inclusion

  • <40 years old
  • Referral for a therapeutic colonoscopy
  • Known Lynch syndrome or Familial Adenomatous Polyposis syndrome
  • Any contraindication for colonoscopy or biopsies of the colon
  • Uncontrolled coagulopathy
  • Confirmed diagnosis of inflammatory bowel disease prior to the scheduled colonoscopy
  • Short bowel or ileostomy
  • Pregnancy

Exclusion criteria for study analysis

  • Colonic inflammation of > 30cm during colonoscopy
  • Incomplete colonoscopy for any reason
  • Incomplete recording or technical failure of the artificial intelligence system

Sites / Locations

  • University Hospitals Leuven

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

AI arm

Arm Description

Only one arm in this study. Every patient who is eligible for this study and is included, after informed consent, will receive a standard colonoscopy combined with real-time AI video analysis

Outcomes

Primary Outcome Measures

Total polyp detection during single pass colonoscopy by the artificial intelligence tool in comparison to polyp detection by the endoscopist with endoscopic diagnosis as a gold standard

Secondary Outcome Measures

Total polyp detection during single pass colonoscopy by the artificial intelligence tool in comparison to polyp detection by the endoscopist with histological diagnosis as a gold standard.
The number of extra detected polyps by artificial intelligence with the endoscopic diagnosis as a gold standard.
The number of extra detected polyps by artificial intelligence with the histological diagnosis as a gold standard
The endoscopist's polyp miss rate defined as the additional detection of polyps during colonoscopy
The false positive rate during clean withdrawal.

Full Information

First Posted
June 18, 2020
Last Updated
November 29, 2022
Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
Nuovo Regina Margherita Hospital, Rome, Italy, Krankenhaus Barmherzige Brüder, Regensburg, Germany, Centre Hospitalier Universitaire de Nantes, Nantes, France, Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warschau, Poland, Spire Portsmouth Hospital, Portsmouth, United Kingdom, University Medical Center, Amsterdam, The Netherlands, University Hospitals Ghent, Ghent, Belgium
search

1. Study Identification

Unique Protocol Identification Number
NCT04442607
Brief Title
Clinical vAliDation of ARTificial Intelligence in POlyp Detection
Acronym
CAD-ARTIPOD
Official Title
Clinical vAliDation of ARTificial Intelligence in POlyp Detection
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
October 13, 2020 (Actual)
Primary Completion Date
October 28, 2022 (Actual)
Study Completion Date
November 29, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
Nuovo Regina Margherita Hospital, Rome, Italy, Krankenhaus Barmherzige Brüder, Regensburg, Germany, Centre Hospitalier Universitaire de Nantes, Nantes, France, Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warschau, Poland, Spire Portsmouth Hospital, Portsmouth, United Kingdom, University Medical Center, Amsterdam, The Netherlands, University Hospitals Ghent, Ghent, Belgium

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is an open label, unblinded, non-randomized interventional study, comparing the investigational artificial intelligence tool with the current "gold standard": Data acquisition will be obtained during one scheduled colonoscopic procedure by a trained endoscopist. During insertion, no action will be taken, colonoscopy is performed following the standard of care. Once withdrawal is started, a second observer (not a trained endoscopist but person trained in polyp recognition) will start the bedside Artificial intelligence (AI) tool, connected to the endoscope's tower, for detection. This second observer is trained in assessing endoscopic images to define the AI tool's outcome. Due to the second observer watching the separate AI screen, the endoscopist is blinded of the AI outcome. When a detection is made by the AI system that is not recognized by the endoscopist, the endoscopist will be asked to relocate that same detection and to reassess the lesion and the possible need of therapeutic action. All detections are separately counted and categorized by the second observer. All polyp detections will be removed following standard of care for histological assessment. The entire colonoscopic procedure is recorded via a separate linked video-recorder.
Detailed Description
This is an investigator-initiated non-randomized prospective interventional trial to validate the performance of a novel state-of-the-art computer-aided detection (CADe) tool for colorectal polyp detection implemented as second observer during routine diagnostic colonoscopy and to evaluate its feasibility in daily endoscopy. Consecutive patients referred for a screening, surveillance or diagnostic colonoscopy will be included. Patients will undergo a standard colonoscopy performed by a trained endoscopist. A second observer, who is not a trained endoscopist, will follow the procedure on a bedside AI-tool to count the number of detections made by the AI system and categorize the results into positive or negative results as follows (1) true positive, (2) false negative or (3) false positive. In case of a detection of the AI-system that was not seen by the endoscopist or unclear to the second observer, the second observer will ask to re-evaluate the indicated region to determine whether after second look the endoscopist has to take extra action. The entire procedure will be recorded. There are no additional risks specific to the use of the AI tool to be taken into account. General risk of colonoscopy (i.e.: perforation, bleeding or post-polypectomy syndrome) could occur with the same frequency as that of a colonoscopy without the use of this AI tool. All patients will receive a standard of care protocol during their colonoscopy. The AI system can only have a beneficial outcome for the patient, a better polyp detection, as it has shown to be non-inferior in terms of accuracy when compared to high detecting endoscopist in our pilot trial

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Polyp of Colon
Keywords
colonic polyps, endoscopy, artificial intelligence

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
This is an investigator-initiated non-randomized prospective interventional trial to validate the performance of a novel state-of-the-art computer-aided detection (CADe) tool for colorectal polyp detection implemented as second observer during routine diagnostic colonoscopy and to evaluate its feasibility in daily endoscopy.
Masking
None (Open Label)
Allocation
N/A
Enrollment
856 (Actual)

8. Arms, Groups, and Interventions

Arm Title
AI arm
Arm Type
Experimental
Arm Description
Only one arm in this study. Every patient who is eligible for this study and is included, after informed consent, will receive a standard colonoscopy combined with real-time AI video analysis
Intervention Type
Device
Intervention Name(s)
artificial intelligence image processing
Intervention Description
Patients will undergo a standard colonoscopy performed by a trained endoscopist. A second observer, who is not a trained endoscopist, will follow the procedure on a bedside AI-tool to count the number of detections made by the AI system and categorize the results into positive or negative results as follows (1) true positive, (2) false negative or (3) false positive.
Primary Outcome Measure Information:
Title
Total polyp detection during single pass colonoscopy by the artificial intelligence tool in comparison to polyp detection by the endoscopist with endoscopic diagnosis as a gold standard
Time Frame
1.5 year
Secondary Outcome Measure Information:
Title
Total polyp detection during single pass colonoscopy by the artificial intelligence tool in comparison to polyp detection by the endoscopist with histological diagnosis as a gold standard.
Time Frame
1.5 year
Title
The number of extra detected polyps by artificial intelligence with the endoscopic diagnosis as a gold standard.
Time Frame
1.5 year
Title
The number of extra detected polyps by artificial intelligence with the histological diagnosis as a gold standard
Time Frame
1.5 year
Title
The endoscopist's polyp miss rate defined as the additional detection of polyps during colonoscopy
Time Frame
1.5 year
Title
The false positive rate during clean withdrawal.
Time Frame
1.5 year
Other Pre-specified Outcome Measures:
Title
Correlation between the Boston Bowel Preparation Score and the number of false positive detections during colonoscopy
Time Frame
1.5 year
Title
Correlation between the endoscopist's historical adenoma detection rate and the number of extra detections and false negative detections by the artificial intelligence system.
Time Frame
1.5 year
Title
Correlation between the polyp size and number of false negatives and additional detections
Time Frame
1.5 year
Title
Correlation between the Paris classification and the number of false negatives and additional detections.
Time Frame
1.5 year
Title
Correlation between the total number of polyps per colonoscopy and additional detections.
Time Frame
1.5 year
Title
Correlation between the experience of the endoscopist and additional detections
Time Frame
1.5 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age ≥40 years Referral for screening, surveillance or diagnostic colonoscopy Able to give informed consent by the patient or by a legal representative Exclusion criteria for study inclusion <40 years old Referral for a therapeutic colonoscopy Known Lynch syndrome or Familial Adenomatous Polyposis syndrome Any contraindication for colonoscopy or biopsies of the colon Uncontrolled coagulopathy Confirmed diagnosis of inflammatory bowel disease prior to the scheduled colonoscopy Short bowel or ileostomy Pregnancy Exclusion criteria for study analysis Colonic inflammation of > 30cm during colonoscopy Incomplete colonoscopy for any reason Incomplete recording or technical failure of the artificial intelligence system
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Raf Bisschops, MD,PhD
Organizational Affiliation
Universitaire Ziekenhuizen KU Leuven
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospitals Leuven
City
Leuven
State/Province
Vlaams-Brabant
ZIP/Postal Code
3000
Country
Belgium

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
We do not plan to make individual participant data available. We might share a overview of anonymized data with the collaborating institutions.

Learn more about this trial

Clinical vAliDation of ARTificial Intelligence in POlyp Detection

We'll reach out to this number within 24 hrs